Scotiabank Initiates Coverage On Vertex Pharmaceuticals With Sector Perform Rating, Announces Price Target of $480
Vertex Pharmaceuticals (VRTX) Ascends But Remains Behind Market: Some Facts to Note
Vertex Pharmaceuticals Is Maintained at Buy by B of A Securities
After eight weeks of selling off, the hedge fund bought back US stocks, achieving the fastest speed since 2021.
The US stock market is currently experiencing active buying and market growth, but the market's high valuation is a concerning issue that may trigger future adjustments.
BofA Securities Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Cuts Target Price to $541
Capricor Reports Positive Long-term Data for DMD Drug Deramiocel
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $473 From $474
Vertex Pharmaceuticals (VRTX) Receives a Hold From Morgan Stanley
7 Children Given Bluebird's Skysona Developed Blood Cancer: Study
Vertex to Announce Third Quarter 2024 Financial Results on November 4th
Raymond James Maintains Vertex Pharmaceuticals(VRTX.US) With Hold Rating
Raymond James Reinstates Market Perform on Vertex Pharmaceuticals
Vertex Pharmaceuticals Inc (VRTX) Q2 2024 Earnings Call Highlights: Navigating Growth Amidst ...
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
Analysts Offer Insights on Healthcare Companies: Teladoc (TDOC), Brookdale Senior Living (BKD) and Vertex Pharmaceuticals (VRTX)
Express News | Vertex Pharmaceuticals Inc : RBC Raises Target Price to $437 From $425
Cathie Wood's ARK Sheds Robinhood Stock, Adds to Amazon and Coinbase
Wells Fargo Tweaks Signature Picks List, Sells AMZN, STZ While Upping MSFT
Cantor Fitzgerald Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $480
Leerink Partners Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Maintains Target Price $600